ArticleJournal of bone oncology2018
Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis.
Article in Journal of bone oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Clinicopathologic significance and prognostic value of circRNAs in osteosarcoma: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.BMC cancer · 2021Pooled it
- Differential Expression of Non-Coding RNAs in Stem Cell Development and Therapeutics of Bone Disorders.Cells · 2023Review
- Identification of Biomarkers for Osteosarcoma Based on Integration Strategy.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Long noncoding RNA HAS2-AS1 accelerates non-small cell lung cancer chemotherapy resistance by targeting LSD1/EphB3 pathway.American journal of translational research · 2020Article
- LncRNA LINC00588 Suppresses the Progression of Osteosarcoma by Acting as a ceRNA for miRNA-1972.Frontiers in pharmacology · 2020Article
- Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway.Journal of bone oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies have reported the relationship between Long non-coding RNAs (LncRNAs) expression and prognosis of osteosarcoma, but less consensus has been reached. Our meta-analysis was conducted to quantitatively assess the relationship between the expression of LncRNAs, prognosis and clinical pathology in osteosarcoma development.
methodsPubMed,Embase,Web of Science,The Cochrane Library,SionMed,CNKI and WanFang databases were carefully searched to identify eligible studies. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the prognostic significance of LncRNAs expression in osteosarcoma. Moreover, meta-regression analysis and subgroup analysis were carried out to explore the potential sources of heterogeneity.
resultsA total of 20 studies comprising 1749 patients were included in present meta-analysis. The results showed that the over-expression of LncRNA had a significant correlation with overall survival (OS) (HR = 2.16, 95% CI:1.68-2.79), and was not related to disease free survival (DFS) (HR = 0.71, 95% CI:0.05-9.53). Subgroup analysis further indicated that LncRNA transcription level was significantly associated with alkaline phosphatase (HR = 2.13, 95% CI:1.58-2.88) , tumor size (< 8/ ≥ 8:HR = 1.97, 95% CI: 1.55-2.62) , metastasis (yes/no: HR = 2.14,95% CI:1.15-3.97) , distant metastasis(presence/absence: HR = 4.02, 95% CI:3.05-5.23) and Enneking stage(IIA /IIB-III:HR = 3.2, 95% CI:2.48-4.14), but not associated with age (≤ 25/ > 25:HR = 1.01, 95% CI:0.78-1.3), gender(female/male: HR = 1.15, 95% CI: 0.96-1.37), tumor site (femur,tibia/elsewhere:HR = 1.15, 95% CI:0.94-1.4) and chemotherapy (yes/no: HR = 1.45, 95% CI:0.46-4.63).
conclusionsThis study demonstrated that abnormal LncRNAs expression might be potential prognostic markers to predict worse overall survival in osteosarcoma patients. However, the cut-off values may be the source of heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.